Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Conditions:   Lung Cancer, Nonsmall Cell;   Thyroid Cancer;   Solid Tumor
Intervention:   Drug: BLU-667
Sponsor:   Blueprint Medicines Corporation
Not yet recruiting - verified January 2017

from #ORL via a.lsfakia on Inoreader http://ift.tt/2kmTky3
via IFTTT

http://ift.tt/2kcz0Nn